查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1624410

全球细胞裂解/细胞分馏市场规模（按细胞类型、最终用户、产品、地区、范围和预测）

Global Cell Lysis/Cell Fractionation Market Size By Type Of Cell, By End User, By Product, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

细胞裂解/细胞分离的市场规模与预测

细胞裂解/细胞分馏市场规模预计在 2023 年达到 45.5 亿美元，到 2030 年将达到 63 亿美元，2024 年至 2030 年的复合年增长率为 7.2%。该市场的成长归因于用于商业诊断和分析应用的细胞培养程序的数量不断增加。预计整个预测期内各种疾病盛行率的持续上升和对新疗法的需求将推动市场扩张。此外，由于各种慢性和非慢性疾病发病率上升导致细胞生物学研究的进步和对蛋白质分析的需求增加，预计将对市场成长产生积极影响。

定义全球细胞裂解/细胞分离市场

细胞裂解/细胞分离是细胞生物学中应用的相关技术，用于打开和分离细胞及其成分。细胞裂解是指细胞破裂并释放其内部成分，如核酸、蛋白质和细胞器。细胞打开可以透过化学方法、机械方法或酵素方法来实现。细胞裂解是多种研究应用中不可或缺的步骤，包括药物开发、蛋白质纯化和 DNA 分离。

细胞分离是裂解后细胞不同成分的分离。该过程透过密度梯度离心、差速离心和其他分离亚细胞或特定细胞器的方法完成。所得材料部分可用于进一步分析。

全球细胞裂解/细胞分离市场概述

民众对个人化医疗的需求不断增长是市场的主要驱动力。个人化医疗具有多种优势，包括客製化治疗、更早发现疾病、降低医疗成本、改善药物开发和更有效率的临床试验。个人化医疗允许医疗专业人员根据患者的情况制定治疗方案。治疗是基于生活方式、特定的遗传倾向和其他因素。这些因素有助于改善治疗结果并降低药物副作用的风险。细胞裂解应用于个人化医疗，以提取和分离与患者治疗或诊断相关的特定分子或细胞类型。

公共和私人机构对生命科学研究的投资不断增加预计将对市场成长产生积极影响。例如，2023年3月，英国政府宣布拨款2.77亿英镑，其中政府将出资1,700万英镑。剩余的 2.6 亿英镑将透过对生命科学製造计画的私人投资来提供，以最大限度地减少对环境的影响，增强健康的復原力，并部署创新以促进国家的发展。这笔资金预计将在全国创造500多个就业岗位，支持该国的经济。

此外，癌症、糖尿病、心血管疾病和关节炎等慢性病的日益普及预计将对市场成长产生积极影响。细胞裂解和分馏是诊断慢性疾病的关键步骤。例如，在诊断类风湿性关节炎等自体免疫疾病时，可以利用细胞裂解法从患者血液中分离自体免疫细胞，并提取 DNA 或 RNA 进行基因表现分析。此步骤可以识别免疫细胞中过度表达或表达不足的特定蛋白质或基因，这有助于诊断疾病和开发个人化药物。

目录

第 1 章全球细胞裂解/细胞分馏市场简介

  • 市场概况
  • 调查范围
  • 先决条件

第 2 章执行摘要

第3章 VERIFIED MARKET RESEARCH研究方法

  • 数据挖掘
  • 验证
  • 一次资料
  • 数据源列表

第 4 章 细胞裂解/细胞分离的全球市场展望

  • 概述
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 波特的五力模型
  • 价值链分析

第5章全球细胞裂解/细胞分离市场（依细胞类型）

  • 概述
  • 哺乳动物细胞
  • 微生物细胞
  • 其他

第6章全球细胞裂解/细胞分离市场（以最终用户划分）

  • 概述
  • 研究机构和研究中心
  • 生物製药和生物技术公司
  • 其他

第7章全球细胞裂解/细胞分馏市场（依产品划分）

  • 概述
  • 机器
    • 超音波仪
    • 均质器
    • 其他设备
  • 消耗品
    • 试剂和试剂盒
    • 珠子
    • 消耗品

第8章全球细胞裂解/细胞分馏市场（按地区）

  • 概述
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东/非洲
    • 阿拉伯联合酋长国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲

第9章全球细胞裂解/细胞分馏市场：竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略
  • 公司区域足迹
  • 按行业划分的企业足迹
  • ACE矩阵

第10章 公司简介

  • Thermo Fisher Scientific Inc.
  • Merck KGAA
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson, and Company
  • Cell Signaling Technology, Inc.
  • MiltenyiBiotec
  • Roche Diagnostics
  • Qiagen N.V.
  • Qsonica有限公司

第11章 重大进展

  • 产品发布/开发
  • 併购
  • 业务拓展
  • 伙伴关係和联盟

第 12 章 附录

  • 相关研究
简介目录
Product Code: 24222

Cell Lysis/Cell Fractionation Market Size And Forecast

Cell Lysis/Cell Fractionation Market size was valued at USD 4.55 Billion in 2023 and is calculated to reach USD 6.3 Billion by 2030, expanding at a CAGR of 7.2% from 2024 to 2030. The market's growth is attributed to the growing number of cultured cell procedures used for commercial diagnostic and analytical applications. The continued rise in the prevalence of various ailments and the demand for novel therapies are projected to drive market expansion throughout the forecast period. Additionally, the growing advances in cell biology research and increased demand for protein analysis due to the increasing prevalence of various chronic and non-chronic conditions are expected to positively influence the market's growth.

Global Cell Lysis/Cell Fractionation Market Definition

Cell lysis and fractionation are related techniques that have applications in cell biology to open and separate cells and their components. Cell lysis refers to breaking the cells open to release the components in the cell, such as nucleic acid, proteins, and cell organelles. The cell's opening is done chemically, mechanically, or enzymatically. Cell lysis is an essential step in several research applications, such as drug development, protein purification, and DNA isolation.

Cell fractionation refers to separating different components of the cell after lysis. The process is carried out through density gradient centrifugation, differential centrifugation, and other methods to isolate subcellular or specific organelles. The fractions of the obtained materials can then be used for further analysis.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Cell Lysis/Cell Fractionation Market Overview

The growing demand for personalized medicine among the population is a key driver for the market. Personalized medicine offers several advantages, such as tailored treatments, early disease detection, reduced healthcare costs, improved drug development, and more efficient clinical trials. Personalized medicines allow healthcare professionals to provide tailored treatment to patients. The treatment is based on lifestyle, specific genetic makeup, and other factors; these factors help to improve the treatment outcomes and reduce the risk of side effects of the drugs. Cell lysis has applications in personalized medicines for extracting and isolating specific molecules or cell types relevant to a patient's treatment and diagnosis.

Growing investments by public and private institutions for research in life sciences are anticipated to impact market growth positively. For instance, in March 2023, the UK government announced funding of GBP 277 Million, wherein the government will contribute GBP 17 Million. The remaining 260 million will be provided through private investments for life science manufacturing projects, minimizing environmental impact, boosting health resilience, and deploying innovations, contributing to the country's growth. The funding is anticipated to support the country's economy by providing more than 500 jobs nationwide.

Additionally, the increasing prevalence of chronic conditions such as cancer, diabetes, cardiovascular diseases, and arthritis, among others, is expected to impact the market growth positively. Cell lysis and fractionation are key steps used to diagnose chronic conditions. For example, diagnosis of autoimmune diseases such as rheumatoid arthritis and cell lysis can be used to isolate autoimmune cells from the patient's blood and extract the DNA or RNA for gene expression analysis. The step helps identify specific proteins and genes that are either over or under-expressed in the immune cells, helping diagnose the disease and develop personalized medicine.

Global Cell Lysis/Cell Fractionation Market: Segmentation Analysis

The Global Cell Lysis/Cell Fractionation Market is Segmented on the basis of Type Of Cell, End User, Product, and Geography.

Cell Lysis/Cell Fractionation Market, By Type Of Cell

  • Mammalian Cells
  • Microbial Cells
  • Others

Based on Type Of Cell, the market is bifurcated into Mammalian Cells, Microbial Cells, and Others. The mammalian cells segment accounted for the highest share in 2022 and is calculated to grow lucratively during the forecast period. The applications of these cells for the bio-manufacturing of vaccines, therapeutic proteins, and other recombinant products are key factors driving the segment's growth.

Cell Lysis/Cell Fractionation Market, By End User

  • Research Laboratories and Institutes
  • Biopharmaceutical and Biotechnology Companies
  • Others

Based on End User, the market is bifurcated into Research Laboratories and Institutes, Biopharmaceutical and Biotechnology Companies, and Others. The Research Laboratories and Institutes segment held the largest market share in 2022 and is calculated to grow lucratively during the forecast period. The growing number of biotechnology institutes and many research activities undertaken by these institutes are driving the market's growth.

Cell Lysis/Cell Fractionation Market, By Product

  • Instruments
  • Sonicator
  • Homogenizers
  • Other Instruments
  • Consumables
  • Reagents and Kits
  • Beads
  • Disposables

Based on Product, the market is bifurcated into Instruments and Consumables. Instruments are classified into sonicators, homogenizers, and other instruments. Consumables are further differentiated into reagents & kits, beads, and disposables. The consumables segment accounted for the highest share in 2022 and is projected to grow lucratively during the forecast period. Repeated purchases, increased funding for cell-based research activities, and the increasing instances of chronic conditions among the population are factors driving the segment's growth.

Cell Lysis/Cell Fractionation Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America
  • On the basis of Regional Analysis, The Global Cell Lysis/Cell Fractionation Market is classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America held the highest share in 2022 and is projected to grow lucratively during the forecast period owing to the technologically advanced R&D infrastructure. Moreover, the regional governments are also providing funding for the development of infrastructure and research projects, which is expected to impact market growth positively.

Key Players

  • The "Global Cell Lysis/Cell Fractionation Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • Thermo Fisher Scientific Inc., Merck KGAA, Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Becton, Dickinson and Company, Cell Signaling Technology, Inc., MiltenyiBiotec, Roche Diagnostics, Qiagen N.V., and Qsonica, LLC., among others.
  • This section provides a company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

  • In November 2022, Merck announced it would acquire Imago BioSciences Inc. The acquisition will help Merck to gain an edge over its competitors for clinical development.
  • Ace Matrix Analysis
  • The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as
  • Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Cell Lysis/Cell Fractionation Market. We cover the major impacting factors driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the Global Cell Lysis/Cell Fractionation Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porter's Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY TYPE OF CELL

  • 6.1 Overview
  • 6.2 Mammalian Cells
  • 6.3 Microbial Cells
  • 6.4 Others

6 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY END USER

  • 7.1 Overview
  • 7.2 Research Laboratories and Institutes
  • 7.3 Biopharmaceutical and Biotechnology Companies
  • 7.4 Others

7 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY PRODUCT

  • 7.1 Overview
  • 7.2 Instruments
    • 7.2.1 Sonicator
    • 7.2.2 Homogenizers
    • 7.2.3 Other Instruments
  • 7.3 Consumables
    • 7.3.1 Reagents and Kits
    • 7.3.2 Beads
    • 7.3.3 Disposables

8 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 The U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 The U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of LATAM
  • 8.6 Middle East and Africa
    • 8.6.1 UAE
    • 8.6.2 Saudi Arabia
    • 8.6.3 South Africa
    • 8.6.4 Rest of the Middle East and Africa

9 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies
  • 9.4 Company Regional Footprint
  • 9.5 Company Industry Footprint
  • 9.6 ACE Matrix

10 COMPANY PROFILES

  • 10.1 Thermo Fisher Scientific Inc.
    • 10.1.1 Company Overview
    • 10.1.2 Company Insights
    • 10.1.3 Business Breakdown
    • 10.1.4 Product Benchmarking
    • 10.1.5 Key Developments
    • 10.1.6 Winning Imperatives
    • 10.1.7 Current Focus & Strategies
    • 10.1.8 Threat from Competition
    • 10.1.9 SWOT Analysis
  • 10.2 Merck KGAA
    • 10.2.1 Company Overview
    • 10.2.2 Company Insights
    • 10.2.3 Business Breakdown
    • 10.2.4 Product Benchmarking
    • 10.2.5 Key Developments
    • 10.2.6 Winning Imperatives
    • 10.2.7 Current Focus & Strategies
    • 10.2.8 Threat from Competition
    • 10.2.9 SWOT Analysis
  • 10.3 Bio-Rad Laboratories, Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Company Insights
    • 10.3.3 Business Breakdown
    • 10.3.4 Product Benchmarking
    • 10.3.5 Key Developments
    • 10.3.6 Winning Imperatives
    • 10.3.7 Current Focus & Strategies
    • 10.3.8 Threat from Competition
    • 10.3.9 SWOT Analysis
  • 10.4 Beckman Coulter, Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Company Insights
    • 10.4.3 Business Breakdown
    • 10.4.4 Product Benchmarking
    • 10.4.5 Key Developments
    • 10.4.6 Winning Imperatives
    • 10.4.7 Current Focus & Strategies
    • 10.4.8 Threat from Competition
    • 10.4.9 SWOT Analysis
  • 10.5 Becton, Dickinson, and Company
    • 10.5.1 Company Overview
    • 10.5.2 Company Insights
    • 10.5.3 Business Breakdown
    • 10.5.4 Product Benchmarking
    • 10.5.5 Key Developments
    • 10.5.6 Winning Imperatives
    • 10.5.7 Current Focus & Strategies
    • 10.5.8 Threat from Competition
    • 10.5.9 SWOT Analysis
  • 10.6 Cell Signaling Technology, Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Insights
    • 10.6.3 Business Breakdown
    • 10.6.4 Product Benchmarking
    • 10.6.5 Key Developments
    • 10.6.6 Winning Imperatives
    • 10.6.7 Current Focus & Strategies
    • 10.6.8 Threat from Competition
    • 10.6.9 SWOT Analysis
  • 10.7 MiltenyiBiotec
    • 10.7.1 Company Overview
    • 10.7.2 Company Insights
    • 10.7.3 Business Breakdown
    • 10.7.4 Product Benchmarking
    • 10.7.5 Key Developments
    • 10.7.6 Winning Imperatives
    • 10.7.7 Current Focus & Strategies
    • 10.7.8 Threat from Competition
    • 10.7.9 SWOT Analysis
  • 10.8 Roche Diagnostics
    • 10.8.1 Company Overview
    • 10.8.2 Company Insights
    • 10.8.3 Business Breakdown
    • 10.8.4 Product Benchmarking
    • 10.8.5 Key Developments
    • 10.8.6 Winning Imperatives
    • 10.8.7 Current Focus & Strategies
    • 10.8.8 Threat from Competition
    • 10.8.9 SWOT Analysis
  • 10.9 Qiagen N.V.
    • 10.9.1 Company Overview
    • 10.9.2 Company Insights
    • 10.9.3 Business Breakdown
    • 10.9.4 Product Benchmarking
    • 10.9.5 Key Developments
    • 10.9.6 Winning Imperatives
    • 10.9.7 Current Focus & Strategies
    • 10.9.8 Threat from Competition
    • 10.9.9 SWOT Analysis
  • 10.10 Qsonica, LLC
    • 10.10.1 Company Overview
    • 10.10.2 Company Insights
    • 10.10.3 Business Breakdown
    • 10.10.4 Product Benchmarking
    • 10.10.5 Key Developments
    • 10.10.6 Winning Imperatives
    • 10.10.7 Current Focus & Strategies
    • 10.10.8 Threat from Competition
    • 10.10.9 SWOT Analysis

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

Related Research